Background: Mathematical models predicting final height (FH) and its standard deviation score (SDS) in children with growth hormone deficiency is an important tool for clinicians to manage treatment process. Previously developed models do not have enough accuracy or are not good enough for practical use.
Objective and hypotheses: We used four binary and seven continuous predictors available at the time of diagnosis and start of therapy and developed multiple linear regression (MLR) models and artificial neural networks (ANN).
Method: The sample included 121 patients of Endocrinology Research Center (Moscow, Russia) who were under observation in 19782016 and reached the final height. All patients were treated by rhGH in daily dose of 0.033 mg/kg at least for 3 years. The input variables obtained at therapy onset include four binary and seven continuous. FH SDS was calculated using Auxology software. Statistica software v.13 (StatSoft, Inc., USA) was used for statistical analysis and ANN development. Different topologies were tested including linear and Bayesian networks, radial basis functions and 3- and 4-layer perceptrons. RMSE and explained variance R2 (%) were the main characteristics of models quality.
Results: MLR models had poor quality. The best ANN predicting FH has RMSE 4.41 cm and explains 75.9% of variance, and 11 predictors are used. The best ANN for predicting FH SDS explains 42.4% of variance and has RMSE 0.601 SDS, and 11 predictors are used. It seems promising to increase the sample and improve the ANN models.
Conclusions: ANN demonstrated to be the efficient approach to mathematical modeling for clinical purposes. The ability to predict the individual effectiveness of growth hormone replacement therapy is of great importance. Based on patients features the endocrinologists are able to manage regime and drug doses. The models provide personalized approach to treatment of patients with GH-deficiency. ANN allows making dose of rhGH and regimen of injection individually adjusted and contribute to improved overall outcomes. ANN can also be useful for evaluating effectiveness of the therapy in patient subgroups and for demonstrating factors determining FH. Prediction models may also reduce the drug costs for GH treatment.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology